Pfizer Inc (PFE) 31.15 $PFE
Global Metastatic Hepatocellular Carcinoma (HCC) Clinical Trials Review 2014
M2 - 6 mins ago
Research and Markets (http://www.researchandmarkets.com/research/z7xx64/metastatic) has announced the addition of the "Metastatic Hepatocellular Carcinoma (HCC) Global Clinical Trials Review, H1, 2014" report to their offering. Metastatic Hepatocellular Carcinoma (HCC) Global Clinical Trials Review, H1, 2014" provides data on the Metastatic Hepatocellular Carcinoma (HCC) clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Metastatic Hepatocellular Carcinoma (HCC). It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Metastatic Hepatocellular Carcinoma (HCC). Espy the commercial landscape of the major Universities / Institutes / Hospitals & Companies - Pfizer Inc. - F. Hoffmann-La Roche Ltd. - AstraZeneca PLC - Bayer AG - Novartis AG - MolMed S.p.A. - Immunomedics, Inc. - Eli Lilly and Company - Affitech A/S - Adherex Technologies Inc. - National Cancer Institute - UNC Lineberger Comprehensive Cancer Center - North Central Cancer Treatment Group - Far Eastern Memorial Hospital - Thomas Jefferson University - Leiden University Medical Center - The University of Hong Kong - University of Florida For more information visit http://www.researchandmarkets.com/research/z7xx64/metastatic
AstraZeneca rejects sweetened Pfizer takeover bid
By DANICA KIRKA - AP - 21 mins ago
LONDON (AP) — The board of pharmaceutical company AstraZeneca on Friday flatly rejected drug maker Pfizer's sweetened takeover offer just hours after it was levelled, describing it as inadequate.
May 2 Premarket Briefing: 10 Things You Should Know
at The Street - 32 mins ago
U.S. stock futures rise ahead of nonfarm payrolls data; AstraZeneca rejects a sweetened bid from Pfizer; Warren Buffet meets shareholders on Saturday; Chevron to report earnings.
Global Squamous Non-Small Cell Lung Carcinoma Clinical Trials Review 2014
M2 - 34 mins ago
Research and Markets (http://www.researchandmarkets.com/research/7vbmxf/squamous) has announced the addition of the "Squamous Non-Small Cell Lung Carcinoma Global Clinical Trials Review, H1, 2014" report to their offering. Squamous Non-Small Cell Lung Carcinoma Global Clinical Trials Review, H1, 2014" provides data on the Squamous Non-Small Cell Lung Carcinoma clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Squamous Non-Small Cell Lung Carcinoma. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Squamous Non-Small Cell Lung Carcinoma. Espy the commercial landscape of the major Universities / Institutes / Hospitals & Companies - Sun Farm Corporation - SCRI Development Innovations, LLC - Pfizer Inc. - Eli Lilly and Company - C. H. Boehringer Sohn AG & Co. KG - Bayer AG - Amgen Inc. - Seoul Veterans Hospital - Washington Hospital Center - Ottawa Hospital Research Institute - Sarah Cannon Research Institute - UCLA's Jonsson Comprehensive Cancer Center - North Central Cancer Treatment Group - National Cancer Institute - The University of Texas M. D. Anderson Cancer Center For more information visit http://www.researchandmarkets.com/research/7vbmxf/squamous
Health Care Stocks Still Healthy Despite Higher Hedging Costs
at The Street - 35 mins ago
Health care is still outperforming the overall indices -- mergers and stellar sales figures and all. Can it be sustained?
European Stocks Flat Ahead of U.S. Jobs Data
at The Street - 44 mins ago
European stock indices tread water on Friday and Asian markets end the day largely in the green.
Pfizer Sends Letter to Rt Hon David Cameron MP Regarding Commitments If Proposed Combination with AstraZeneca is Completed
Business Wire - Fri May 02, 1:11AM CDT
--Substantial R&D innovation hub in Cambridge to be completed
Pfizer Confirms Delivery of Increased Proposal to AstraZeneca
Business Wire - Fri May 02, 1:08AM CDT
--Proposal represents a 39% premium to the closing price of £35.86 on 3 January 2014, being the trading day immediately prior to the date of Pfizer's January proposal
Second Genome Enters Into Agreement with Pfizer Inc. on Microbiome Research Initiative in Obesity
PR Newswire - Thu May 01, 11:01PM CDT
Second Genome announced today that it has entered into an agreement with Pfizer Inc. to conduct extensive microbiome research in a large observational study aimed at gaining new insights into obesity and metabolic disease. The goal of the study is to evaluate numerous clinical factors and the microbiome in a select cohort of approximately 900 individuals with varying metabolic phenotypes, in order to better understand the inter-relationship between the microbiome, obesity and metabolic disorders.
Most active New York Stock Exchange-traded stocks
AP - Thu May 01, 5:08PM CDT
NEW YORK (AP) — A look at New York Stock Exchange 10 most-active stocks at the close of trading:
Final Glance: Pharmaceuticals companies
AP - Thu May 01, 5:07PM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies were mixed at the close of trading:
What's With All The Healthcare And Pharmaceutical Mergers?
at The Street - Thu May 01, 4:25PM CDT
James Dennin, Kapitall: Last Tuesday alone saw the announcement of $74 billion in potential healthcare and pharmaceutical mergers. In one day. [...]
Midday Glance: Pharmaceuticals companies
AP - Thu May 01, 12:46PM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 1 p.m.:
Dow Today: Pfizer (PFE) Lower
at The Street - Thu May 01, 12:00PM CDT
Holding back the Dow today is Pfizer (NYSE: PFE ), which is lagging the broader Dow index with an 11-cent decline (-0.3%) bringing the stock to $31.17.
Why AstraZeneca (AZN) Stock Is Higher Today
at The Street - Thu May 01, 11:07AM CDT
Shares of AstraZeneca (AZN) are up 2.40% after it was reported that Pfizer (PFE) is preparing to sweeten its bid for the biopharmaceutical company to over $106 billion.
Early Glance: Pharmaceuticals companies
AP - Thu May 01, 10:10AM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 10 a.m.:
Global Metastatic Colorectal Cancer Clinical Trials Review 2014: Espy the Commercial Landscape of the Major Institutes & Companies
M2 - Thu May 01, 9:57AM CDT
Research and Markets (http://www.researchandmarkets.com/research/4jtbsc/metastatic) has announced the addition of the "Metastatic Colorectal Cancer Global Clinical Trials Review, H1, 2014" report to their offering. Metastatic Colorectal Cancer Global Clinical Trials Review, H1, 2014" provides data on the Metastatic Colorectal Cancer clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Metastatic Colorectal Cancer. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Metastatic Colorectal Cancer. Espy the commercial landscape of the major Universities / Institutes / Hospitals & Companies - F. Hoffmann-La Roche Ltd. - Amgen Inc. - Sanofi - Pfizer Inc. - E. Merck KG - Eli Lilly and Company - Bristol-Myers Squibb Company - Novartis AG - Bayer AG - AstraZeneca PLC - National Cancer Institute - Memorial Sloan Kettering Cancer Center - The University of Texas M. D. Anderson Cancer Center - Grupo Espanol de Tratamiento de Tumores Digestivos - Epidemiological and Clinical Research Information Network - European Organization for Research and Treatment of Cancer - Gruppo Oncologico del Nord-Ovest - NCIC Clinical Trials Group - Duke University For more information visit http://www.researchandmarkets.com/research/4jtbsc/metastatic
June 13th Options Now Available For Pfizer (PFE)
at The Street - Thu May 01, 9:45AM CDT
Investors in Pfizer Inc saw new options become available today, for the June 13th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the PFE options chain for the new June 13th contracts and identified one put and one...
Pfizer (PFE) Approaches New Downside Target of $30.76
Comtex SmarTrend(R) - Thu May 01, 9:31AM CDT
Shares of Pfizer (NYSE
FE) have bearishly opened below the pivot of $31.48 today and have reached the first support level of $31.02. Should the shares continue to fall, the support pivots of $30.76 and $30.04 will be of interest.
Global Metastatic Hepatocellular Carcinoma (HCC) Clinical Trials Review 2014
M2 - 6 mins ago
Research and Markets (http://www.researchandmarkets.com/research/z7xx64/metastatic) has announced the addition of the "Metastatic Hepatocellular Carcinoma (HCC) Global Clinical Trials Review, H1, 2014" report to their offering. Metastatic Hepatocellular Carcinoma (HCC) Global Clinical Trials Review, H1, 2014" provides data on the Metastatic Hepatocellular Carcinoma (HCC) clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Metastatic Hepatocellular Carcinoma (HCC). It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Metastatic Hepatocellular Carcinoma (HCC). Espy the commercial landscape of the major Universities / Institutes / Hospitals & Companies - Pfizer Inc. - F. Hoffmann-La Roche Ltd. - AstraZeneca PLC - Bayer AG - Novartis AG - MolMed S.p.A. - Immunomedics, Inc. - Eli Lilly and Company - Affitech A/S - Adherex Technologies Inc. - National Cancer Institute - UNC Lineberger Comprehensive Cancer Center - North Central Cancer Treatment Group - Far Eastern Memorial Hospital - Thomas Jefferson University - Leiden University Medical Center - The University of Hong Kong - University of Florida For more information visit http://www.researchandmarkets.com/research/z7xx64/metastatic
AstraZeneca rejects sweetened Pfizer takeover bid
By DANICA KIRKA - AP - 21 mins ago
LONDON (AP) — The board of pharmaceutical company AstraZeneca on Friday flatly rejected drug maker Pfizer's sweetened takeover offer just hours after it was levelled, describing it as inadequate.
May 2 Premarket Briefing: 10 Things You Should Know
at The Street - 32 mins ago
U.S. stock futures rise ahead of nonfarm payrolls data; AstraZeneca rejects a sweetened bid from Pfizer; Warren Buffet meets shareholders on Saturday; Chevron to report earnings.
Global Squamous Non-Small Cell Lung Carcinoma Clinical Trials Review 2014
M2 - 34 mins ago
Research and Markets (http://www.researchandmarkets.com/research/7vbmxf/squamous) has announced the addition of the "Squamous Non-Small Cell Lung Carcinoma Global Clinical Trials Review, H1, 2014" report to their offering. Squamous Non-Small Cell Lung Carcinoma Global Clinical Trials Review, H1, 2014" provides data on the Squamous Non-Small Cell Lung Carcinoma clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Squamous Non-Small Cell Lung Carcinoma. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Squamous Non-Small Cell Lung Carcinoma. Espy the commercial landscape of the major Universities / Institutes / Hospitals & Companies - Sun Farm Corporation - SCRI Development Innovations, LLC - Pfizer Inc. - Eli Lilly and Company - C. H. Boehringer Sohn AG & Co. KG - Bayer AG - Amgen Inc. - Seoul Veterans Hospital - Washington Hospital Center - Ottawa Hospital Research Institute - Sarah Cannon Research Institute - UCLA's Jonsson Comprehensive Cancer Center - North Central Cancer Treatment Group - National Cancer Institute - The University of Texas M. D. Anderson Cancer Center For more information visit http://www.researchandmarkets.com/research/7vbmxf/squamous
Health Care Stocks Still Healthy Despite Higher Hedging Costs
at The Street - 35 mins ago
Health care is still outperforming the overall indices -- mergers and stellar sales figures and all. Can it be sustained?
European Stocks Flat Ahead of U.S. Jobs Data
at The Street - 44 mins ago
European stock indices tread water on Friday and Asian markets end the day largely in the green.
Pfizer Sends Letter to Rt Hon David Cameron MP Regarding Commitments If Proposed Combination with AstraZeneca is Completed
Business Wire - Fri May 02, 1:11AM CDT
--Substantial R&D innovation hub in Cambridge to be completed
Pfizer Confirms Delivery of Increased Proposal to AstraZeneca
Business Wire - Fri May 02, 1:08AM CDT
--Proposal represents a 39% premium to the closing price of £35.86 on 3 January 2014, being the trading day immediately prior to the date of Pfizer's January proposal
Second Genome Enters Into Agreement with Pfizer Inc. on Microbiome Research Initiative in Obesity
PR Newswire - Thu May 01, 11:01PM CDT
Second Genome announced today that it has entered into an agreement with Pfizer Inc. to conduct extensive microbiome research in a large observational study aimed at gaining new insights into obesity and metabolic disease. The goal of the study is to evaluate numerous clinical factors and the microbiome in a select cohort of approximately 900 individuals with varying metabolic phenotypes, in order to better understand the inter-relationship between the microbiome, obesity and metabolic disorders.
Most active New York Stock Exchange-traded stocks
AP - Thu May 01, 5:08PM CDT
NEW YORK (AP) — A look at New York Stock Exchange 10 most-active stocks at the close of trading:
Final Glance: Pharmaceuticals companies
AP - Thu May 01, 5:07PM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies were mixed at the close of trading:
What's With All The Healthcare And Pharmaceutical Mergers?
at The Street - Thu May 01, 4:25PM CDT
James Dennin, Kapitall: Last Tuesday alone saw the announcement of $74 billion in potential healthcare and pharmaceutical mergers. In one day. [...]
Midday Glance: Pharmaceuticals companies
AP - Thu May 01, 12:46PM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 1 p.m.:
Dow Today: Pfizer (PFE) Lower
at The Street - Thu May 01, 12:00PM CDT
Holding back the Dow today is Pfizer (NYSE: PFE ), which is lagging the broader Dow index with an 11-cent decline (-0.3%) bringing the stock to $31.17.
Why AstraZeneca (AZN) Stock Is Higher Today
at The Street - Thu May 01, 11:07AM CDT
Shares of AstraZeneca (AZN) are up 2.40% after it was reported that Pfizer (PFE) is preparing to sweeten its bid for the biopharmaceutical company to over $106 billion.
Early Glance: Pharmaceuticals companies
AP - Thu May 01, 10:10AM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 10 a.m.:
Global Metastatic Colorectal Cancer Clinical Trials Review 2014: Espy the Commercial Landscape of the Major Institutes & Companies
M2 - Thu May 01, 9:57AM CDT
Research and Markets (http://www.researchandmarkets.com/research/4jtbsc/metastatic) has announced the addition of the "Metastatic Colorectal Cancer Global Clinical Trials Review, H1, 2014" report to their offering. Metastatic Colorectal Cancer Global Clinical Trials Review, H1, 2014" provides data on the Metastatic Colorectal Cancer clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Metastatic Colorectal Cancer. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Metastatic Colorectal Cancer. Espy the commercial landscape of the major Universities / Institutes / Hospitals & Companies - F. Hoffmann-La Roche Ltd. - Amgen Inc. - Sanofi - Pfizer Inc. - E. Merck KG - Eli Lilly and Company - Bristol-Myers Squibb Company - Novartis AG - Bayer AG - AstraZeneca PLC - National Cancer Institute - Memorial Sloan Kettering Cancer Center - The University of Texas M. D. Anderson Cancer Center - Grupo Espanol de Tratamiento de Tumores Digestivos - Epidemiological and Clinical Research Information Network - European Organization for Research and Treatment of Cancer - Gruppo Oncologico del Nord-Ovest - NCIC Clinical Trials Group - Duke University For more information visit http://www.researchandmarkets.com/research/4jtbsc/metastatic
June 13th Options Now Available For Pfizer (PFE)
at The Street - Thu May 01, 9:45AM CDT
Investors in Pfizer Inc saw new options become available today, for the June 13th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the PFE options chain for the new June 13th contracts and identified one put and one...
Pfizer (PFE) Approaches New Downside Target of $30.76
Comtex SmarTrend(R) - Thu May 01, 9:31AM CDT
Shares of Pfizer (NYSE
FE) have bearishly opened below the pivot of $31.48 today and have reached the first support level of $31.02. Should the shares continue to fall, the support pivots of $30.76 and $30.04 will be of interest. 
